CD4 regulatory T cells in human cancer pathogenesis

Keith L Knutson, Mary L. Disis, Lupe G. Salazar

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Over the past decade, there has been an accelerated understanding of immune regulatory mechanisms. Peripheral immune regulation is linked to a collection of specialized regulatory cells of the CD4+ T cell lineage (i.e., CD4+ Tregs). This collection consists of Tregs that are either thymically derived (i.e., natural) or peripherally induced. Tregs are important for controlling potentially autoreactive immune effectors and immunity to foreign organisms and molecules. Their importance in maintaining immune homeostasis and the overall health of an organism is clear. However, Tregs may also be involved in the pathogenesis of malignancies as now compelling evidence shows that tumors induce or recruit CD4+ Tregs to block immune priming and antitumor effectors. Efforts are underway to develop approaches that specifically inhibit the function of tumor-associated Tregs which could lead to an increased capability of the body's immune system to respond to tumors but without off-target immune-related pathologies (i.e., autoimmune disease). In this review, the biology of human CD4+ Tregs is discussed along with their involvement in malignancies and emerging strategies to block their function.

Original languageEnglish (US)
Pages (from-to)271-285
Number of pages15
JournalCancer Immunology, Immunotherapy
Volume56
Issue number3
DOIs
StatePublished - Mar 2007

Fingerprint

Regulatory T-Lymphocytes
Neoplasms
Cell Lineage
Autoimmune Diseases
Immune System
Immunity
Homeostasis
Pathology
T-Lymphocytes
Health

Keywords

  • CD25
  • Foxp3
  • IPEX
  • Ontak
  • Toxin
  • Tregs

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

CD4 regulatory T cells in human cancer pathogenesis. / Knutson, Keith L; Disis, Mary L.; Salazar, Lupe G.

In: Cancer Immunology, Immunotherapy, Vol. 56, No. 3, 03.2007, p. 271-285.

Research output: Contribution to journalArticle

Knutson, Keith L ; Disis, Mary L. ; Salazar, Lupe G. / CD4 regulatory T cells in human cancer pathogenesis. In: Cancer Immunology, Immunotherapy. 2007 ; Vol. 56, No. 3. pp. 271-285.
@article{3eeddafe8e214b43ad4d1706fe31b54c,
title = "CD4 regulatory T cells in human cancer pathogenesis",
abstract = "Over the past decade, there has been an accelerated understanding of immune regulatory mechanisms. Peripheral immune regulation is linked to a collection of specialized regulatory cells of the CD4+ T cell lineage (i.e., CD4+ Tregs). This collection consists of Tregs that are either thymically derived (i.e., natural) or peripherally induced. Tregs are important for controlling potentially autoreactive immune effectors and immunity to foreign organisms and molecules. Their importance in maintaining immune homeostasis and the overall health of an organism is clear. However, Tregs may also be involved in the pathogenesis of malignancies as now compelling evidence shows that tumors induce or recruit CD4+ Tregs to block immune priming and antitumor effectors. Efforts are underway to develop approaches that specifically inhibit the function of tumor-associated Tregs which could lead to an increased capability of the body's immune system to respond to tumors but without off-target immune-related pathologies (i.e., autoimmune disease). In this review, the biology of human CD4+ Tregs is discussed along with their involvement in malignancies and emerging strategies to block their function.",
keywords = "CD25, Foxp3, IPEX, Ontak, Toxin, Tregs",
author = "Knutson, {Keith L} and Disis, {Mary L.} and Salazar, {Lupe G.}",
year = "2007",
month = "3",
doi = "10.1007/s00262-006-0194-y",
language = "English (US)",
volume = "56",
pages = "271--285",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "3",

}

TY - JOUR

T1 - CD4 regulatory T cells in human cancer pathogenesis

AU - Knutson, Keith L

AU - Disis, Mary L.

AU - Salazar, Lupe G.

PY - 2007/3

Y1 - 2007/3

N2 - Over the past decade, there has been an accelerated understanding of immune regulatory mechanisms. Peripheral immune regulation is linked to a collection of specialized regulatory cells of the CD4+ T cell lineage (i.e., CD4+ Tregs). This collection consists of Tregs that are either thymically derived (i.e., natural) or peripherally induced. Tregs are important for controlling potentially autoreactive immune effectors and immunity to foreign organisms and molecules. Their importance in maintaining immune homeostasis and the overall health of an organism is clear. However, Tregs may also be involved in the pathogenesis of malignancies as now compelling evidence shows that tumors induce or recruit CD4+ Tregs to block immune priming and antitumor effectors. Efforts are underway to develop approaches that specifically inhibit the function of tumor-associated Tregs which could lead to an increased capability of the body's immune system to respond to tumors but without off-target immune-related pathologies (i.e., autoimmune disease). In this review, the biology of human CD4+ Tregs is discussed along with their involvement in malignancies and emerging strategies to block their function.

AB - Over the past decade, there has been an accelerated understanding of immune regulatory mechanisms. Peripheral immune regulation is linked to a collection of specialized regulatory cells of the CD4+ T cell lineage (i.e., CD4+ Tregs). This collection consists of Tregs that are either thymically derived (i.e., natural) or peripherally induced. Tregs are important for controlling potentially autoreactive immune effectors and immunity to foreign organisms and molecules. Their importance in maintaining immune homeostasis and the overall health of an organism is clear. However, Tregs may also be involved in the pathogenesis of malignancies as now compelling evidence shows that tumors induce or recruit CD4+ Tregs to block immune priming and antitumor effectors. Efforts are underway to develop approaches that specifically inhibit the function of tumor-associated Tregs which could lead to an increased capability of the body's immune system to respond to tumors but without off-target immune-related pathologies (i.e., autoimmune disease). In this review, the biology of human CD4+ Tregs is discussed along with their involvement in malignancies and emerging strategies to block their function.

KW - CD25

KW - Foxp3

KW - IPEX

KW - Ontak

KW - Toxin

KW - Tregs

UR - http://www.scopus.com/inward/record.url?scp=33845933229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845933229&partnerID=8YFLogxK

U2 - 10.1007/s00262-006-0194-y

DO - 10.1007/s00262-006-0194-y

M3 - Article

C2 - 16819631

AN - SCOPUS:33845933229

VL - 56

SP - 271

EP - 285

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 3

ER -